Search company, investor...

Founded Year



Series A | Alive

Total Raised


Last Raised

$670K | 3 yrs ago

About Pill Connect

Pill Connect is a company that focuses on medicine adherence monitoring in the healthcare sector. The company offers a smart dosing system that attaches to standard medicine bottles, recording each pill dispensed and providing real-time, remote tracking of medication adherence. This service is primarily used in clinical trials to monitor patient adherence and inform trial outcomes. Pill Connect was formerly known as eLucid mHealth. It was founded in 2013 and is based in Manchester, England.

Headquarters Location

125 Deansgate

Manchester, England, M3 2BY,

United Kingdom


Pill Connect's Product Videos

Pill Connect's Products & Differentiators

    Pill Connect Smart Dispenser

    Smart dispenser for solid oral dose medicines. Attaches to most standard medicine bottles. Gives patients a button that lets them dispense dose electronically. The dose delivered can be programmed with the drug regimen. Dispensing is recorded and can be read by external devices to send to remote monitoring platforms.


Expert Collections containing Pill Connect

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Pill Connect is included in 1 Expert Collection, including Digital Health.


Digital Health

10,595 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.

Pill Connect Patents

Pill Connect has filed 2 patents.

The 3 most popular patent topics include:

  • clinical research
  • dietary supplements
  • health informatics
patents chart

Application Date

Grant Date


Related Topics




Dietary supplements, Clinical research, Health informatics, Pharmaceutical industry, Medical terminology


Application Date


Grant Date



Related Topics

Dietary supplements, Clinical research, Health informatics, Pharmaceutical industry, Medical terminology



Latest Pill Connect News

AARDEX Group and Pill Connect Ltd Partner to Empower Patient Adherence

Feb 4, 2021

AARDEX Group and Pill Connect Ltd Partner to Empower Patient Adherence Integrated Digital Solutions Enhance Solid Oral Dose Medication Adherence Measurement Liege, February 2nd 2021 – Belgium-based AARDEX Group, the world leader in medication adherence solutions, today announced a strategic partnership with Pill Connect Ltd, an English company specializing in the design, development and manufacture of innovative medical devices for dispensing solid oral dose medication. The collaboration will link AARDEX’s proprietary Medication Event Monitoring System (MEMS®) with Pill Connect’s add-on solutions for drug delivery devices. The combined system has significant potential to radically influence patients’ adherence performance. Through this strategic alliance, AARDEX will reinforce its comprehensive portfolio of smart solutions and connected devices available to effectively measure and manage medication adherence for patients and healthcare providers. There are significant benefits to be gained from ecosystems that seamlessly measure and analyze patient adherence to medications in clinical trials. The successful management of this is supported by research settings and professional healthcare systems. The first initiative will integrate Pill Connect’s smart dosing system with AARDEX’s MEMS Adherence Software (MEMS AS®) for medicines delivered in solid oral dose form. The collaboration will start in academic research, followed by drug development clinical trials, and then extended to commercialized drugs and real-life conditions. David Dalla Vecchia, CEO and Financial Lead of AARDEX Group, commented, “Smart packaging is one of the most reliable ways to accurately measure, describe, manage and influence patient adherence in relation to medication. It highly correlates with patient behaviour, making the results highly valuable. It is a proven way to minimize risk while being a seamless experience for patients. The objective is to support an unbiased and precise measure of medication adherence in key therapy areas, not only for commercialized drugs and real-life conditions, but also clinical trials and drug efficacy. This partnership will also be pivotal in enhancing the impact of academic research findings.”   James Burnstone, CEO of Pill Connect Ltd commented, “Managing patient compliance can make the difference between failed and successful clinical trials. The combination of Pill Connect’s smart dosing systems with the AARDEX MEMS AS® system ensures the precise capture and analysis of data for clinical trials and adherence monitoring. We are delighted to be collaborating to bring these solutions to our customers. For clinical trials, the integration of this kind of tool will improve the speed and accuracy of medication adherence assessment and intervention efficacy and potentially decrease the rate of unnecessary mediation, bolstering success at every level.” AARDEX is passionate about continuously innovating data-driven medication adherence solutions to enhance digital therapeutics and patient empowerment. Evidence-based digital adherence monitoring systems can help improve clinical results and conclusions, maximizing the chances of success in clinical trials. Sponsors can improve drug efficacy by managing patient adherence to the study medications and pharma companies can reliably and seamlessly monitor and address patient medication adherence, minimizing risks of trial failure or costly adjustments. About AARDEX Group                                                                                                         AARDEX Group is the world leader in digital solutions to measure and manage medication adherence. With operations in Belgium, Switzerland and the U.S., AARDEX develops and markets digital solutions for adherence-enhancing strategies in clinical trials, research settings, and professional healthcare systems. AARDEX is the central actor of a complete ecosystem that combines its MEMS® Adherence Software with a wide range of smart packages and devices that measure patient adherence across all routes of drug administration. AARDEX’ vision is to continuously innovate in data-driven medication adherence solutions to enhance digital therapeutics and patient empowerment. About Pill Connect Ltd Pill Connect Ltd is a health technology company based in Manchester, UK developing smart solutions to improve patient care. Pill Connect’s smart dispensing system which aims to improve and monitor patient adherence, concluded its first clinical trials in 2019. For Media Enquiries:  Sophie Beattie

Pill Connect Frequently Asked Questions (FAQ)

  • When was Pill Connect founded?

    Pill Connect was founded in 2013.

  • Where is Pill Connect's headquarters?

    Pill Connect's headquarters is located at 125 Deansgate, Manchester.

  • What is Pill Connect's latest funding round?

    Pill Connect's latest funding round is Series A.

  • How much did Pill Connect raise?

    Pill Connect raised a total of $670K.

  • Who are the investors of Pill Connect?

    Investors of Pill Connect include Catapult Ventures, Jonathan Milner, Shallcross Partners, GM&C Life Sciences Fund and Deepbridge Capital.

  • Who are Pill Connect's competitors?

    Competitors of Pill Connect include AiCure.

  • What products does Pill Connect offer?

    Pill Connect's products include Pill Connect Smart Dispenser.


Compare Pill Connect to Competitors

AdhereTech Logo

AdhereTech is a digital health company that operates in the healthcare sector. The company provides a smart system for medication management, offering real-time medication reminders and early intervention services to patients. It primarily serves the healthcare industry, partnering with pharmaceutical manufacturers, specialty pharmacies, and healthcare teams. It was founded in 2011 and is based in New York, New York.

MediSafe Logo

MediSafe develops a medication engagement platform. The company offers a medication management platform that provides services such as medication adherence and persistence, patient and caregiver support, and coordination of access to medications. It primarily serves the healthcare industry. The company was founded in 2012 and is based in Needham, Massachusetts.

Scene Health Logo
Scene Health

Scene develops a mobile health platform for remote healthcare management. It uses video technology and human engagement to help patients take doses of medication as prescribed. The company operates through dose-by-dose observation and clinical assessment of potential administration problems such as technique and side effects. It was formerly known as emocha Health. The company was founded in 2018 and is based in Baltimore, Maryland.

Dimagi Logo

Dimagi is a global social enterprise that focuses on powering impactful frontline work through scalable digital solutions and services in the technology and healthcare sectors. The company offers data collection software and digital health solutions, including mobile, web, and SMS applications that enable frontline workers to deliver services. Dimagi primarily sells to the healthcare, education, nutrition, and agriculture sectors. It was founded in 2002 and is based in Cambridge, Massachusetts.


AiCure operates as an artificial intelligence (AI) and advanced data analytics company targeting the healthcare industry. It uses artificial intelligence (AI) to understand people's responses regarding clinical trials and patient care. The company was founded in 2010 and is based in New York, New York.

Proteus Digital Health

Proteus Digital Health is a digital medicine the measures medication treatment effectiveness and helps physicians improve clinical outcomes. It is comprised of ingestible sensors, a small wearable sensor patch, an application on a mobile device, and a provider portal. Once activated, Proteus unlocks never-before-seen insight into patient health patterns and medication treatment effectiveness, leading to more informed healthcare decisions


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.